Sanofi Has The Fire Power For Deals, CEO Hudson Says
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
You may also be interested in...
Sanofi’s Q4 update will highlight planned strategic changes and Dupixent’s key growth role, amid a strong rebound in quarterly US flu vaccine sales.
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model.